A  scientific forum held in HCM City on April 27 announced a pioneering preventive method to help prevent lower respiratory ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody nirsevimab, in a prefilled injection used ...

The company plans to introduce Beyfortus, which contains the monoclonal antibody, nirsevimab, in a prefilled injection used ...

Dr Reddy's Laboratories has partnered with Sanofi Healthcare to introduce Beyfortus, a novel drug for RSV prevention in ...

Eucalyptus oil extracted from the leaves of the eucalyptus tree can act as a complementary therapy in providing respiratory ...

Dr Reddy’s Laboratories on Monday said it has expanded its strategic partnership with French biopharma giant Sanofi’s Indian ...

The researchers said that efficacy of nirsevimab seen in the controlled settings of a clinical trial may not fully reflect ...

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

Monoclonal antibody nirsevimab provides strong real-world protection against severe RSV in infants, suggests meta-analysis ...

Dr Reddy’s and Sanofi partner to launch Beyfortus, a novel drug to prevent respiratory syncytial virus in infants.

"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 ...